Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Vyriad, Inc.
Study ID
NCT02919449
Phase
PHASE1
Status
Terminated

Conditions

  • Recurrent Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MV-NIS — BIOLOGICAL
    This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
  • Atezolizumab — BIOLOGICAL
    Atezolizumab will be administered every 3 weeks

Study Details

This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.

Key Dates

Start date
Aug 3, 2017
Status verified
Jan 2022
Primary completion
Jan 19, 2018
Completion
Jan 19, 2018

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: MV-NIS and Atezolizumab
    MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) of MV-NIS in Combination With Atezolizumab [ Time Frame: 28 days after MV-NIS administration for each dose cohort ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905-

Find similar trials in Rochester, MN

By research site
Mayo Clinic· Rochester, MN

Related Studies